B. Riley Financial reissued a "buy" rating and set a $19.00 price target (up from $18.00) on shares of Adherex Technologies in a research note on Monday...
B. Riley Financial reissued a "buy" rating and set a $19.00 price target (up from $18.00) on shares of Adherex Technologies in a research note on Monday...
Adherex Technologies (FENC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 57.8% upside potential for Adherex Technologies (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Fennec Pharmaceuticals (NASDAQ:FENC) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...
Adherex Technologies (FENC) delivered earnings and revenue surprises of +33.33% and +3.69%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +20.00% and -5.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Adherex Technologies (FENC) delivered earnings and revenue surprises of +400.00% and +11.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +39.58% and +30.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?